Projeto: COMPETE2030-FEDER-00910400- JANUS

Designação do projeto:	JANUS - Reengenharia do rastreio do cancro do colo do útero para o século XXI: ação conjunta para um programa de rastreio novo, atual e sustentável
Código do projeto:	COMPETE2030-FEDER-00910400- JANUS
Região de Intervenção:	Norte
Instituição proponente/ Promotor líder/ Entidade coordenadora:	Instituto de Saúde Pública da Universidade do Porto
Parceiro(s) / Co-promotor(es) / Instituição(ões) participante(s):	Faculdade de Medicina da Universidade do Porto; Instituto Português de Oncologia do Porto; Unidade Local de Saúde de Gaia e Espinho, E.P.E.
Data de início:	2025-01-01
Data de conclusão:	2027-12-31

Objetivos, atividades e resultados esperados/atingidos

The primary objectives are:
1) To compare the adherence to CCS based on self-sampling (for HrHPV testing) with screening based on sampling for liquid-based cytology (LBC)-based HPV testing performed by a health professional (the current standard of care), in a non-inferiority framework of analysis;
2) To compare the adherence to CCS based on self-sampling, followed by LBC-based HPV testing for the non-adherent to self-sampling, with the current standard of care, in a superiority framework of analysis;
3) To compare the adherence to CCS based on self-sampling, followed by LBC-based HPV testing for the non-adherent to self-sampling, with the current standard of care followed by self-sampling for the non-adherent to the standard of care, in a non-inferiority framework of analysis;
4) To assess biomarker performance of DNA methylation markers for high-grade squamous intraepithelial lesions or worse (HSIL+) detection, in different contexts of population-based CCS, involving self-sampling and LBC HPV testing performed by a health professional, used alone or sequentially.
Secondary objectives include stratifi ed analyses in sub-groups of the population defi ned according to age, deprivation index of the place of residence, CCS history and organization model of the primary healthcare units.This study uses a randomized design for assessing the effect of using self-sampling instead of the standard of care, but also the effect of two alternative options for the sequential incorporation of self-sampling in the screening process, namely self-sampling as the primary option, complemented (among women non-adherent to self-sampling) by collection of the sample by a health professional, versus the standard of care, complemented (among women non-adherent) by self-sampling. Furthermore, the assessment of performance of methylation markers will determine whether a full molecular flow may be feasible, enabling the exclusive use of self-collected samples and precluding the need for a subsequent LBC collection in HrHPV positive cases identifi ed in self-collected samples.

Recomendar Página Voltar ao Topo

Copyright 1996-2025 © Faculdade de Medicina Dentária da Universidade do Porto I Termos e Condições I Acessibilidade I Índice A-Z
Página gerada em: 2025-09-27 às 19:38:28 | Política de Privacidade | Política de Proteção de Dados Pessoais | Denúncias | Livro Amarelo Eletrónico